Journal Article Summary
The article investigates the interaction between GSK3640254, a new HIV maturation inhibitor, and combined oral contraceptives (COCs) containing ethinyl oestradiol and levonorgestrel in healthy women. This research is important because many women living with HIV may need to use both antiretroviral therapy and contraceptives, and understanding potential drug interactions is crucial for ensuring effective treatment and preventing unintended pregnancies. The study aims to determine whether GSK3640254 affects the pharmacokinetics (how the body processes the drugs) and pharmacodynamics (the effects of the drugs on the body) of the contraceptives.
In this phase I study, 23 healthy women participated, with 17 completing the trial. The women took ethinyl oestradiol and levonorgestrel for ten days, followed by a combination of these contraceptives with GSK3640254 for an additional eleven days. The results showed that GSK3640254 did not significantly alter the levels of ethinyl oestradiol or levonorgestrel in the blood, indicating no harmful interactions. While some participants experienced elevated liver enzymes, these were likely related to the contraceptive rather than GSK3640254.
The study has some limitations, including a small sample size and the fact that some participants withdrew due to adverse effects, which may affect the generalizability of the findings. Patients should be aware that while the study suggests that GSK3640254 can be safely combined with COCs, there were instances of elevated liver enzymes that warrant monitoring. It is advisable for individuals using these medications to discuss their treatment plans with a healthcare professional to ensure safety and efficacy, especially if they have pre-existing liver conditions or are taking other medications.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Pene Dumitrescu Teodora, Greene Thomas J., Joshi Samit R., Xu Jianfeng, Johnson Mark, Halliday Fiona, Butcher Laurie, Zimmerman Eric, et al.. Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women. British Journal of Clinical Pharmacology 2021. DOI: 10.1111/bcp.15051. PMID: 34427938. PMCID: PMC9291532.
Featured Pill Pals Product
My Way (Levonorgestrel) 1.5 mg Tablet - Generic For Plan B and Morning After Pill --- Lupin Pharma
My Way (Levonorgestrel) 1.5 mg Tablet - Generic For Plan B and Morning After Pill is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
